News Feeds

It is impossible to get rid of anxiety because it exists to help us, says cognitive psychotherapist Owen O'Kane. Instead, he suggests three ways to reframe your relationship with anxiety in order to take back control

We recently discussed the different types of worlds that the Habitable Worlds Observatory (HWO) is expected to find that might have noticeable biosignatures. However, no matter how good the instrumentation on board the observatory is, the data it collects will be useless if scientists don’t know how to interpret it. A paper explaining what data they need to collect before analyzing HWO data was authored by Niki Parenteau, a research biologist at NASA, and her co-authors, which is now available in pre-print on arXiv.

Regular Mark Sturtevant (as opposed to Irregular Mark Sturtevant) has sent in some lovely insect photos to fill the nearly-empty reserve of pictures. Please send any good wildlife photos you have. Thanks!

Mark’s captions are indented, and you can enlarge his photos by clicking on them. Be sure to check out the female Tussock Moth caterpillar with vestigial wings (it’s the eighth photo).

Here is another dispatch of local insects and spiders, all photographed either in area parks near where I live in eastern Michigan, or as staged shots at home. Let’s start with a couple of dragonflies. First up is a Green Darner (Anax junius), which ranks pretty large among the dragonflies found here. As is almost always the case, this individual is a female, since they perch frequently and are much easier to approach than males, which I only rarely manage to photograph. Do you see the tiny yellow critter on the dragonfly? That is a Globular Springtail, and it must have walked or jumped onto the dragonfly from nearby foliage. There may be a few more of them in the picture as well, though I’m not certain. Springtails are tiny soil arthropods, and they are extremely abundant. When seen up close, Globular Springtails are arguably adorable, as you can see in the linked image. I’ve searched for them for some time but have only rarely encountered them, despite claims that they are exceedingly common. Perhaps our local species spends more time up on foliage rather than in the soil, meaning I’ve been looking in the wrong places!:

The next dragonfly is a male Skillet Clubtail (Gomphurus ventricosus), named for the large, pan-like club on the end of its abdomen. I have to drive a few hours south to a particular park to see them, and of course this one is perching on poison ivy which covers much of the area there. That park hosts 8 or 9 species of clubtails according to a dragonfly documentation site called Odonata Central. I’ve photographed most of those species with only two left to find:

A field near my workplace has a ridiculously high population of Chinese Praying Mantids (Tenodera sinensis). I suspect this is the lingering result of someone having released a large number of egg cases several years ago, combined with a robust population of grasshopper prey. Shown here is a young June nymph. I can return later in the summer to find several large adults in no time at all:

Next up are some lepidopterans. First is a Hackberry Emperor butterfly (Asterocampa celtis). They are often common along forest margins where their host Hackberry trees [Celtis occidentalis] are concentrated. Their caterpillars, however, seem to be quite secretive, as I’ve seen only a few of them:

Next is an inchworm caterpillar, though I don’t have an identification for it. Do you see the tiny mites?:

The insect shown next is a moth, although it makes a very convincing wasp mimic. This is the Eupatorium Borer Moth (Carmenta bassiformis). The larvae feed on the roots of Ironweed and Joe Pye Weed, both of which are highly valued native wildflowers because they are very much favored by butterflies:

The flamboyant caterpillar in the next image is a White-marked Tussock Caterpillar (Orgyia leucostigma). I’ve tried several times to get an acceptable focus-stacked image of one of these. What makes them difficult is the combination of all those oddly angled sticky-out bits, which challenge the shallow depth of field inherent in this kind of photography, along with the fact that these caterpillars absolutely will Not Hold Still. As a result, the stacking is done on the fly, followed later by long hours of manual reassembly of the jumbled focus stack. This image is by far my most successful attempt:

I kept this caterpillar in hopes that the moth emerging from the cocoon would be a female. Why? Well—check out what came out! It was a female! Females have barely visible vestigial wings, and I had never seen one before. She will sit here, unmoving, until a male finds her. This strategy saves a great deal of energy that can instead be used for laying eggs. The winged males are unremarkable, and while I’ve probably seen them, I don’t think I’ve ever photographed one:

Finally, here are three images of jumping spiders I’ve been wanting to share together for quite some time. The Dimorphic Jumping Spider (Maevia inclemens) is a species I regularly see around the outside of our house. The name refers to the males having two distinct color morphs. The images below are manual focus stacks, photographed in staged settings on the ‘ol dining room table. First is a female with long-legged fly prey, which conveniently provides a sense of scale since the fly is about the size of a mosquito:

Next are the two male color morphs. The first somewhat resembles the females, while the other is very different and comes with distinctive hair decorations. This is an older image, but I’m bringing it back so all three forms can finally be shown together. It’s surprising that they are all the same species!

I recently learned that the two male forms use different courtship displays for females, yet are considered equally successful in the mating game. I’m sure Jerry can steer things in the right direction if I am in error here, but having different male forms with different mating strategies does not seem unusual in the animal kingdom. Examples I’m familiar with include lizards, crustaceans, and fish, although in those cases the different males include those that are aggressive and territorial, and others that win by being sneaky. But here, I don’t see how either male is territorial, and apparently both have courtship displays for females.

One of my goals for next season will be to try to document their different courtship behaviors. That seems do-able, since I can expect to find several of them again next summer.

Quantum computers could revolutionize everything from drug discovery to business analytics—but their incredible power also makes them surprisingly vulnerable. New research from Penn State warns that today’s quantum machines are not just futuristic tools, but potential gold mines for hackers. The study reveals that weaknesses can exist not only in software, but deep within the physical hardware itself, where valuable algorithms and sensitive data may be exposed.

After the Big Bang, the Universe entered a long, dark period before the first stars formed. During this era, hydrogen emitted a faint radio signal that still echoes today. New simulations show this signal could be slightly altered by dark matter, leaving behind a measurable fingerprint. Future radio telescopes on the Moon may be able to detect it and shed light on one of astronomy’s greatest mysteries.

Astronomers have captured the most dramatic view yet of a planet losing its atmosphere, watching the ultra-hot gas giant WASP-121b for an entire orbit with the James Webb Space Telescope. Instead of a single stream of escaping gas, the planet is wrapped in two colossal helium tails—one trailing behind like a comet, the other stretching ahead toward its star.

Spacecraft orbiting the Red Planet have helped researchers map out an ancient coastline that surrounded a large ocean billions of years ago

Traditional intuit whale acupuncture.

The post Pet Acupuncture and Life first appeared on Science-Based Medicine.

Concerns around common sunscreen chemicals have prompted the search for natural alternatives, with lignin from wood being one of the most promising candidates

A century-old hoax takes wing again, proof that good stories never stay buried.

Learn about your ad choices: dovetail.prx.org/ad-choices

A nearby active galaxy called VV 340a offers a dramatic look at how a supermassive black hole can reshape its entire host. Astronomers observed a relatively weak but restless jet blasting outward from the galaxy’s core, wobbling like a spinning top as it plows through surrounding gas. Using a powerful mix of space- and ground-based telescopes, the team showed that this jet heats, ionizes, and flings gas out of the galaxy at a surprisingly high rate.

NASA’s Artemis II rocket has reached its launch pad after a painstaking overnight crawl across Kennedy Space Center. Engineers are now preparing for crucial fueling and countdown tests ahead of the first crewed Artemis mission. The mission will send four astronauts on a journey around the Moon and back. It’s a key milestone on the path to returning humans to the Moon and pushing onward to Mars.

Astronomers at the University of Warwick have discovered that black holes don’t just consume matter—they manage it, choosing whether to blast it into space as high-speed jets or sweep it away in vast winds.

Hydrogen Cyanide, which is toxic, may have played an important role in the emergence of life. Its unique properties, especially in frigid environments in space, may have helped generate the complex molecules necessary for life to appear.

A new compass for the SKEPDOC column. This column was founded by Harriet Hall, MD (1945–2023) who wrote it from 2006 to 2023. In 2026, we welcome William Meller, MD, to the helm. As an expert in evolutionary medicine, Dr. Meller will be our guide in navigating the deep biological history of our species to find the “True North” of human health.

I have been practicing medicine for more than 40 years. During that time the management of obesity and Type 2 diabetes (T2DM)—the kind that usually is caused by being overweight—often felt like Sisyphus pushing a boulder up a hill, only to have it roll back down, often heavier than before. We faced a “diabesity” epidemic where the available tools were blunt instruments at best.

Lifestyle interventions—meaning trying to get someone to change their behavior—was the most and least effective method we had. Most, because in the less than two percent of patients who were successful, it works very well. Least, because, well … 98 percent failed. And they failed because all of our evolutionary history (“See food? Eat it!”) was working against them. This is the mismatch theory: a mismatch between the environment of our evolutionary ancestry that designed our brains to seek foods that were at once rare and nutritious (sweets and fats) and the modern environment in which such foods are in such overabundance that we eat far beyond the saturation point. 

The pharmacological options were often disappointing: Sulfonylureas and insulin lower blood sugar but caused weight gain, exacerbating the underlying problem. Bariatric surgery works, but it is invasive and carries surgical as well as lifelong nutritional risks. 

When we look at the data for GLP receptor agonists, along with the innumerable before and after photos of successful weight loss transformations, we are forced to admit that we have moved from a realm of wishful thinking into one of potent pharmacology.

Into this therapeutic desert crawled the Gila Monster (above), a venomous lizard native to the American Southwest from which researchers derived GLP receptor agonists (Glucagon-like peptide-1 receptor agonists)—medications that mimic the natural GLP-1 hormone that lead to lower blood sugar, help control appetite, and promote weight loss by telling the pancreas to release more insulin when glucose is high, slowing the rate of stomach emptying, and signaling to the brain a sense of fullness. 

As a skeptic, I am allergic to the word “miracle,” but when we look at the data for GLP receptor agonists, along with the innumerable before and after photos of successful weight loss transformations, we are forced to admit that we have moved from a realm of wishful thinking into one of potent pharmacology. But, as always in medicine, there is no free lunch. 

The Incretin Concept: From Gut to Glory 

The story begins with the “incretin effect”—the observation that glucose taken by mouth triggers a much stronger insulin response by increasing the production of hormones in the pancreas, compared to when it is injected directly into a vein. The gut knows you are eating and tells the pancreas to get ready to pack away the extra calories as fat. In patients with Type 2 diabetes, this effect is blunted and the sugar floats around in the bloodstream much longer. 

Scientists identified two main hormones responsible: Glucose-dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide (GLP-1). The problem is that GIP doesn’t work well in diabetics. GLP-1 works beautifully—stimulating insulin, suppressing glucagon, and slowing gastric emptying—but it has a fatal flaw: It is destroyed by the enzyme DPP-4 within minutes of entering the bloodstream. 

This led to two distinct pharmaceutical strategies. The earlier version was DPP-4 Inhibitors. Drugs like the “Gliptins” block DPP-4, making GLP-1 last longer. They are well-tolerated but their ability to lower blood sugar is modest and they generally do not cause weight loss. 

The newer strategy was to engineer versions of GLP to resist degradation. This is where the Gila monster strolled in. In the 1990s, while researching hormone-like drugs, Dr. John Eng noted a similarity between exendin-4 found in Gila venom to Glucagon-like peptide (GLP), and it was able to resist breakdown by DPP! 

The Evidence: Efficacy Beyond the Hype 

The first GLP-1 agonist, exenatide (Byetta, approved in 2005), required twice-daily injections and produced modest weight loss. But the pharmacology evolved rapidly. We moved to once-daily liraglutide, and then to the once-weekly heavyweights: dulaglutide, semaglutide (Ozempic and Wegovy), and the dual GIP and GLP-1 agonist tirzepatide (Mounjaro and Zepbound). 

The clinical trials, called LEAD, SUSTAIN, PIONEER, STEP, and SURPASS (you’ve got to just love the creative acronyms!) have generated data that are hard to dismiss: 

Glycemic Control: These drugs consistently outperform most oral antidiabetics in lowering blood sugar by 10 to 20 percent. 

Weight Loss: This is the game changer. While early drugs produced 2–4 kg of weight loss over six months, the newer agents are producing results previously only seen with surgery. In the STEP-1 trial, semaglutide 2.4 mg resulted in an approximately 15 percent body weight reduction. Tirzepatide pushed this further, achieving up to 22 percent weight loss in the SURMOUNT-1 trial. That is the effect of a 250-pound person losing 55 pounds! Who wouldn’t want some of that?! 

Cardiovascular Outcomes: Perhaps most importantly, these drugs are not like some that just make numbers look better; they are saving lives. Liraglutide and semaglutide have demonstrated significant reductions in major adverse cardiovascular events (MACE), including heart attack and stroke, in high-risk populations. The SELECT trial recently showed semaglutide reduces MACE by 20 percent even in nondiabetic patients with cardiovascular disease. But don’t be fooled, it is not likely that these drugs have specific effects on the heart. It is probable that the fat loss alone is causing these benefits. 

Some Skeptical Scrutiny: The Risks 

If a drug sounds too good to be true, we must look for the catch. GLP-1 agonists have plenty.

The “Puke” Diet? The most common side effects of GLP-1 agonists are gastrointestinal: nausea, vomiting, diarrhea, and bloating. In some trials, up to 45 percent of patients experienced nausea. While this usually subsides, it raises a valid question: Are people losing weight because their metabolism is optimized, or because they feel too sick to eat? The mechanism involves central appetite suppression in the hypothalamus, but the “gastric braking” effect is real and unpleasant for many. 

The Pancreas and Thyroid Scare. Early observational data suggested a link between GLP-1 agonists and pancreatitis and pancreatic cancer. However, extensive reviews have not confirmed a causal link to pancreatic cancer, though a slight increase in pancreatitis persists in some data. This makes sense, as one of the major sites of GLP’s effects is on the pancreas. In the thyroid, these drugs cause C-cell tumors in rodents. Humans have far fewer GLP-1 receptors on their thyroid C-cells than rats, and so far no evidence of increased thyroid cancer has been confirmed in humans. Still, the Black Box warning remains: If you have a family history of endocrine tumors or medullary thyroid cancer, these drugs are not for you. 

If we are simply shrinking patients without preserving their strength, we may be trading one set of problems for another.

Vanishing Muscle. Weight loss via GLP-1 agonists is not just fat loss, so overall body composition must be monitored. In the STEP-1 trial, DEXA scans showed that lean body mass (muscle and bone) accounted for nearly 40 percent of the weight lost. In older adults, this raises the specter of “sarcopenic obesity”—being frail and weak despite having excess fat. Losing muscle mass compromises physical function and metabolic health. If we are simply shrinking patients without preserving their strength, we may be trading one set of problems for another. Now, regular and increased exercise is part of the prescription for all patients taking GLP drugs, but studies on how well this works are still in progress. 

The Perioperative Peril. Because GLP-1 agonists delay gastric emptying, there have been reports of patients aspirating (inhaling) gastric contents during anesthesia, even after standard fasting protocols. This is a new, practical safety concern that surgical societies are rushing to address. 

Mental Health. Reports of suicidal ideation appeared in postmarketing monitoring of GLP-1 agonist users, prompting investigations by European regulators. However, recent large cohort studies have not supported an increased risk of suicidality compared to other diabetes medications. As with all centrally acting drugs, vigilance is required, but the current data are reassuring. 

A Lifetime Prescription? The most significant caveat for GLP-1 agonists is durability. Obesity can be a chronic, relapsing disease. Trials show that when patients stop taking semaglutide, they regain two-thirds of the lost weight within a year, and cardiometabolic improvements revert toward baseline. This implies that these are not “cures” but lifelong therapies, much like blood pressure medication. 

Financial Toxicity. As I write this, these drugs are prohibitively expensive, creating a massive public health gap. We also saw shortages that left diabetic patients unable to fill prescriptions because the supply was diverted to off-label weight loss use. GLP-1 agonists are not expensive to produce, however, and the patent on Ozempic expired in January of 2026 in Canada and China (and lasts until 2030 in the U.S.), but I expect the market to bring the costs down dramatically over the next few years. As of this year, close to 12 percent of Americans have tried it at least once. 

Needles Versus Pills 

If there is one thing that holds patients back from the current crop of injectable incretins it is the needle. Despite the efficacy of weekly injections, people prefer pills. The pharmaceutical industry, never one to leave money on the table, has been racing to develop an oral alternative that doesn’t require the strict fasting rituals of earlier attempts like oral semaglutide. Enter orforglipron, the latest contender in the “nonpeptide small molecule” class, which promises the benefits of GLPs without the injection or the fuss. 

Unlike existing peptide predecessors that are digested by stomach acid unless armored with absorption enhancers, orforglipron is a chemical—a small molecule designed to survive the GI tract and activate the GLP-1 receptor directly. The data from the ATTAIN-1 trial, published in September 2025, look good. Patients on the 36 mg dose achieved an average weight loss of 11.2 percent over 72 weeks, compared to just 2.1 percent for placebo. No needles. And this pill does not require the “empty stomach, no water, wait 30 minutes” song-and-dance required by oral semaglutide; it can be taken with or without food. 

These are serious medications with serious side effects, and they may require lifelong commitment.

However, let’s look a little past the convenience. While an 11.2 percent average weight loss is clinically significant, it trails behind the 13.7 percent average reduction seen with semaglutide and 20.2 percent with tirzepatide. Furthermore, the biology of GLP-1 agonism remains the same regardless of delivery method: You cannot cheat physiology. In the ATTAIN-1 trial, adverse events led to treatment discontinuation in up to 10.3 percent of patients on the drug, compared to only 2.7 percent on placebo. The side effects are the usual suspects—gastrointestinal distress, nausea, and constipation—confirming that oral delivery does not bypass the “gastric braking” misery. 

We must also remain vigilant regarding safety. The development of a similar small molecule, lotiglipron, was unceremoniously halted due to liver toxicity concerns. While orforglipron has passed its Phase 3 hurdles without these specific signals so far, the history of pharmacology teaches us that rare, serious adverse events often lurk in the postmarketing shadows. 

Additionally, while proponents argue that small molecules are cheaper to manufacture than biologics, whether those savings will be passed on to the patient or simply absorbed into the profit margins remains to be seen, with projected self-pay costs in some cases exceeding $1,000 per month. Orforglipron represents a technological leap, but it is not a magic wand; it is simply a more convenient way to induce the same physiological trade-offs we have seen over the last several years with the shots. 

Conclusion 

Prior to the incretin era, our ability to manage the twin epidemics of diabetes and obesity was dishearteningly limited. GLP-1 receptor agonists represent a hard-earned pharmacological breakthrough, offering potent glucose control and unprecedented weight loss. 

However, skepticism is still warranted regarding their indiscriminate use. They are already being used in numerous off-label ways, like shedding a few pounds before a wedding, allegedly decreasing cravings for addictive drugs like alcohol and narcotics, and purportedly even for the treatment of Alzheimer’s and Parkinson’s disease. There are ongoing studies for these uses, but early data are weak and the risks are unknown. These are serious medications with serious side effects, and they may require lifelong commitment. 

Caveat emptor.

Humans have always been fascinated with space. We frequently question whether we are alone in the universe. If not, what does intelligent life look like? And how would aliens communicate?

Deep beneath the surface of distant exoplanets known as super-Earths, oceans of molten rock may be doing something extraordinary: powering magnetic fields strong enough to shield entire planets from dangerous cosmic radiation and other harmful high-energy particles.

I’ve often pointed out that the mainstream media seems curiously soft on religion, taking the stance that religion is good for America and can heal it in these troubled times. But they never ask—and don’t seem to care—whether religion is true.  Instead, they insist that filling the “God-shaped hole”—a spiritual lacuna that supposedly exists in all of us—is what we need to be complete and happy human beings.

The New York Times is particularly guilty of pushing superstition as a nostrum. For two years, until 2023, they had a regular column and newsletter called “On Faith,” by Tish Harrison Warren, an Anglican priest who relentlessly pushed religion. (You can see my many posts criticizing her here.)  There were, of course, no atheists writing to point out that the God that Warren extolled weekly didn’t seem to exist.

Now Lauren Jackson, who professes nonbelief but is a spiritual “seeker”, has replaced Warren with a weekly newsletter and column called “Believing”. You can see the list of her columns here, and my post about the column here. Here’s one example below (click to read, or find it (archived here)

Jackson mourns her inability to fully believe:

I recognize, though, that my spiritual longing persists — and it hasn’t been sated by secularism. I want a god. I live an ocean away from that small Arkansas chapel, but I still remember the bliss of finding the sublime in the mundane. I still want it all to be true: miracles, souls, some sort of cosmic alchemy that makes sense of the chaos.

For years, I haven’t been able to say that publicly. But it feels like something is changing. That maybe the culture is shifting. That maybe we’re starting to recognize that it’s possible to be both believing and discerning after all.

I don’t think so—not without evidence for God.  Can you be discerning and believe in the Loch Ness Monster? That would be easier than believing in God, for at least there used to be some (now discredited) evidence for Nessie.

Here’s another more recent one (click to read), a column that proves that God is made in the image of humans and not the other way around:

A quote:

Reverend Albert Cleage, a leader in the Detroit civil rights movement, wanted to counter what he saw as white dominance of Christianity. He was also trying to make the church into an important center for Black political power. So he and his team commissioned an artist, Glanton Dowdell, to replace the old church building’s iconography, which at the time depicted a white pilgrim. Dowdell scouted a young Black mother and her 3-year-old son at a laundromat and told her she had a memorable face — a crisp jawline and sharp cheekbones. Would she allow him to paint her as a Black Mary?

She said yes. The resulting mural was radical for the time, but it served to both illustrate and venerate an emerging doctrine of Black liberation theology. Cleage was developing a gospel of Black nationalism, one that claimed Jesus was a Black revolutionary whose identity as such had been obscured by white people.

“The basic problem facing Black people is their powerlessness,” he once said.

Look, I don’t care what color God is, because I’m fully convinced that God is a man-made fiction. He’s a coloring book in the mind, and you can make God whatever sex or ethnicity you want. But none of that makes God’s existence more probable.

It’s curious that Jackson, who professes nonbelief, only writes positively about it, and doesn’t allow an atheistic point of view in her column. Though she herself is an unbeliever, you won’t see her discuss the problems with religion, nor will you see her write about Islam, save for tiny mentions. That’s because her brief is to console NYT readers by allowing them to think that religion is compatible with a modern, scientific outlook. Jackson, I believe, replaced Warren because Warren’s take on faith was too strong and was alienating readers. So the paper got themselves a “none” who writes good things about faith.

This also applies to the Free Press, whose softness on religion I’ve often mentioned. This piece, for example, came out just last week:

Here’s an excerpt:

There’s something simple yet profound about mingling with people who are different. At its very best, religion can tamp down feelings of distrust, disenchantment, and disconnection. At their very best, religious institutions are places where people from every economic background and political affiliation can set aside their differences and worship together. Instead of churches being engines of social capital generation and catalysts for building trust and tolerance, the growing polarization of American religion has left us lonelier, angrier, sicker, and more divided than ever before.

. . . . I am under no illusion that American religion is the greatest panacea for all that ails the United States. But people gathering under one roof to sing together, pray together, and work in common cause to create a better community and a better society will certainly move us closer to the ideals that were set forth by the Founding Fathers of our country. There’s nothing simpler and more consequential than people getting up on a Sunday morning, getting dressed, and making their way to a local house of worship.

For religion to effect these changes, isn’t it true that worshipers must share common beliefs about what’s true, and foremost among them must be the existence of God?  Well, no, because I have friends who are atheists and nevertheless go to church for the social aspects: the singing, the fellowship, the comity based on a false premise that Kurt Vonnegut called a “granfaloon.” Oh, that we could have a latter-day Mencken, who made his name in journalism even though he wrote stuff like this!:

Faith may be defined briefly as an illogical belief in the occurrence of the improbable.

The most curious social convention of the great age in which we live is the one to the effect that religious opinions should be respected.

Religion is fundamentally opposed to everything I hold in veneration – courage, clear thinking, honesty, fairness, and, above all, love of the truth.

We must respect the other fellow’s religion, but only in the sense and to the extent that we respect his theory that his wife is beautiful and his children smart. Mencken regularly railed against religion, and with good reason.  But the idea of a modern Mencken publishing this kind of stuff is inconceivable. Though more people than ever have given up belief or are “nones,” the curious respect for religion remains.

The strange principle of quantum entanglement baffled Albert Einstein. Yet finally putting quantum weirdness to the ultimate test, and embracing the results, turned out to be a revolutionary idea

It never used to be possible to attribute individual weather events to climate change and map their full consequences. Thanks to the work of two pioneering climate scientists, it is now